A study to compare effectiveness and safety of a combination of vudalimab or pembrolizumab with chemotherapy in participants with advanced lung cancer.

You likely can't join if

• Subjects who meet any of the following criteria will be excluded from the study: 1. Participation in a study of an investigational agent or device within 4 weeks prior to planned start of study treatment 2. Expected to require any other anticancer therapy while on study 3. Major surgery within 3 weeks of planned start of study treatment 4. Have known active central nervous system metastases and/or carcinomatous meningitis. Patients with treated brain metastases may participate, provided they are radiologically stable (ie, are without evidence of progression for ≥ 4 weeks by repeat imaging performed during the screening period, are clinically stable, and are without requirement of steroid treatment for ≥ 7 days prior to the first dose of study treatment) 5. For patients treated in the neoadjuvant or adjuvant setting: • Failure to recover from any other cancer therapy-related toxicity (other than immune-related toxicity) related to previous anticancer treatment to ≤ Grade 2 • History of a life-threatening (Grade 4) immune-mediated adverse event associated with prior administration of an immunotherapy agent • Failure to recover from any immunotherapy-related toxicity from prior cancer therapy to ≤ Grade 1, except that subjects are eligible if a previous immunotherapy-related endocrinopathy is medically managed with hormone replacement therapy only or if immune-mediated alopecia has not resolved • Known history of severe hypersensitivity to monoclonal antibody therapy • Known history of hypersensitivity to platinum-based chemotherapy or pemetrexed 6. Active known or suspected autoimmune disease 7. Has any condition requiring systemic treatment with corticosteroids, (> 10 mg daily prednisone equivalents) , or other immunosuppressive medications within 14 days prior to first dose of study drug (except that inhaled or topical corticosteroids or brief courses of corticosteroids given for prophylaxis of contrast dye allergic response are permitted) 8. Receipt of an organ allograft
• 9. Evidence of any serious bacterial, viral, parasitic, or systemic fungal infection within the 30 days prior to the first dose of study drug 10. Interstitial lung disease that is symptomatic or a history of pneumonitis requiring systemic glucocorticoid treatment. Lymphangitic spread of NSCLC is not an exclusion. 11. Receipt of a live-virus vaccine within 30 days prior to first dose of study drug 12. Known human immunodeficiency virus (HIV) positive with CD4+ T-cell (CD4+) count < 350 cells/μL, or an HIV viral load greater than 400 copies/mL, or a history of an acquired immunodeficiency syndrome-defining opportunistic infection within the past 12 months, or not on established antiretroviral therapy (ART) for at least 4 weeks prior to initiation of study drug dosing. 13. Positive test for hepatitis C RNA 14. Positive test for hepatitis B surface antigen (hBsAg) or hepatitis B core antibody (hBcAb); a patient whose hBsAg is negative and hBcAb is positive may be enrolled if a hepatitis B virus (HBV) DNA test is negative and the subject is retested for HbsAg and HBV DNA every 2 months 15. History or evidence of any other clinically unstable/uncontrolled disorder, condition, or disease (including, but not limited to, cardiopulmonary, renal, metabolic, hematologic, or psychiatric) other than NSCLC, that, in the opinion of the Investigator, would pose a risk to patient safety or interfere with study evaluations, procedures, or completion 16. Positive pregnancy test (ie, human chorionic gonadotropin); planning to become pregnant while enrolled in the study, or breastfeeding for up to 120 days after the last dose of vudalimab or pembrolizumab, and 180 days after the last dose of chemotherapy. 17. Prisoner or involuntarily incarcerated